Clay Siegall’s Contribution In The Biotechnology Industry

Dr. Clay Siegall is the co-founder of a renowned biotechnology company, Seattle Genetics. He has made significant contribution in the industry by researching on cancer therapies. His involvement in the field of cancer therapy was inspired by his painful experience of losing his father to cancer. In the past, the field of oncology had limited resources. Clay studied Genetics at the George Washington University with the objective of improving the situation. For thirty years, Clay has spent each day working towards developing viable cancer treatments. He believes in staying informed through learning and interacting with different experts. Clay enhances the growth of Seattle Genetics by partnering with other players in the industry. Through this strategy, he has managed to advance the company’s ADC technology by investing in new ideas to help treat cancer.

About Clay Siegall

Clay Siegall serves as the president and CEO of Seattle Genetics. He is also the chairman of the board. Seattle Genetics is run on the foundation of scientific innovation, in-depth research and drug development practices. These elements have contributed to the success of the company. Seattle Genetics is a leader in the development of Antibody-drug conjugates. Clay enabled the company to secure FDA’s approval in 2011 for ADCETRIS. The company has collaborated with Takeda Pharmaceutical Company to sell ADCETRIS in more than 65 countries. In addition, Clay Siegall has made much success with Seattle Genetics. He has played a pivotal role in advancing a diverse pipeline of ADCs, securing multiple strategic licenses for ADC technology with several companies, and funding the company’s activities. Recently, he raised over $1.2 billion.

Previously, he worked for Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute and National Institutes of Health. Presently, he serves on the boards of Directors of Alder BioPharmaceuticals, Washington Roundtable and Ultragenyx Pharmaceutical. He is a recipient of several awards, including the University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. In 2012, he received the Pacific Northwest Ernst & Young Entrepreneur of the Year. Clay holds 15 patents. In addition, he has authored over 70 publications. Clay graduated with a B.S. in zoology from the University of Maryland.